Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

NCT03029585 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Ovarian Carcinoma

Interventions

DRUG: NanoPac® 100 mg/m2
DRUG: NanoPac® 200 mg/m2
DRUG: NanoPac® 300 mg/m2
DRUG: NanoPac® 400 mg/m2
DRUG: Standard of Care Intravenous Chemotherapy

Sponsor

NanOlogy, LLC

Collaborators

[object Object]